Avid: Quick and early

There is keen interest in developing early diagnostics for degenerative diseases where early therapeutic intervention is likely to provide the greatest benefit but diagnosis is still largely dependent on an assessment of symptoms. Avid Radiopharmaceuticals Inc. is developing a pipeline of targeted radioactive small molecules that it hopes may one day allow for routine early screening for Alzheimer's disease, Parkinson's disease/dementia with Lewy bodies (DLB) and diabetes.

Avid (Philadelphia, Penn.) has four programs in development for use with either SPECT or PET imaging - AD SPECT, AD PET, PD/DLB PET and diabetes PET - with multiple proprietary compounds in each program...